6978.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 16:08):
Our systems believe the stock currently is overvalued by -0.24% compare to its pairs and should correct downwards.

Stats
今日成交量	71 000
平均成交量	106 595
市值	1.98B
EPS	HKD-0.210 ( Q4 \| 2023-12-31 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-5.50 (Sector) 14.27 (Industry) 6.31
ATR14	HKD0 (0.00%)

0690.HK 0.00%

1061.HK -0.82%

1167.HK 3.31%

1177.HK -1.11%

1228.HK 0.00%

1477.HK 1.63%

1521.HK -2.44%

1530.HK 2.71%

1548.HK -1.42%

1672.HK -3.61%

1873.HK 0.00%

1875.HK -0.45%

1877.HK -0.51%

1952.HK -2.59%

2096.HK -0.69%

2126.HK -2.00%

2137.HK -0.98%

2142.HK 1.47%

2157.HK -3.80%

2162.HK -2.88%

2171.HK -2.04%

2179.HK -3.00%

2197.HK -1.45%

2256.HK -0.61%

2257.HK 0.00%

2616.HK 2.70%

2696.HK -0.65%

3759.HK -1.63%

6160.HK 1.17%

6600.HK 0.86%

6622.HK 0.71%

6628.HK 1.33%

6821.HK -0.10%

6826.HK 1.76%

6978.HK 23.00%

6996.HK 0.00%

6998.HK 0.00%

9688.HK -0.15%

9926.HK -2.33%

9939.HK -4.59%

9966.HK -0.41%

9969.HK 3.66%

9995.HK -4.67%

相关性 (AI algo v.1.1b): Overvalued: -0.24% HKD3.86 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

Immunotech Biopharm Ltd 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Immunotech Biopharm Ltd 财务报表

Annual	2023
营收:	HKD0
毛利润:	HKD0 (0.00 %)
EPS:	HKD-0.650

FY	2023
营收:	HKD0
毛利润:	HKD0 (0.00 %)
EPS:	HKD-0.650

FY	2022
营收:	HKD0
毛利润:	HKD0 (0.00 %)
EPS:	HKD-0.690

FY	2021
营收:	HKD0.00
毛利润:	HKD0.00 (0.00 %)
EPS:	HKD-0.708

Financial Reports:

No articles found.

Immunotech Biopharm Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Immunotech Biopharm Ltd

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.